Literature DB >> 25998279

A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder.

E Sherwood Brown1, Jackie Peterson Todd1, Lisa T Hu1, Joy M Schmitz1, Thomas J Carmody1, Alyson Nakamura1, Prabha Sunderajan1, A John Rush1, Bryon Adinoff1, Mary Ellen Bret1, Traci Holmes1, Alexander Lo1.   

Abstract

OBJECTIVE: Although drug dependence is common in patients with bipolar disorder, minimal data are available on the treatment of drug dependence in this patient population. The authors previously reported a decreased risk of relapse to cocaine use in a pilot study of citicoline in patients with bipolar disorder and cocaine dependence. The primary aim of the present study was to determine whether citicoline reduces cocaine use in outpatients with bipolar I disorder and current cocaine dependence and active cocaine use.
METHOD: A total of 130 outpatients with bipolar I disorder (depressed or mixed mood state) and cocaine dependence received citicoline or placebo add-on therapy for 12 weeks. Results of thrice-weekly urine drug screens were analyzed using a generalized linear mixed model that was fitted to the binary outcome of cocaine-positive screens at each measurement occasion for 12 weeks. Mood was assessed with the Inventory of Depressive Symptomatology-Self Report, the Hamilton Depression Rating Scale, and the Young Mania Rating Scale.
RESULTS: In the intent-to-treat sample (N=61 in both groups), significant treatment group and group-by-time effects were observed, whether or not missing urine screens were imputed as cocaine positive. The group effect was greatest early in the study and tended to decline with time. No between-group differences in mood symptoms or side effects were observed.
CONCLUSIONS: Citicoline was well tolerated for treatment of cocaine dependence in patients with bipolar disorder. Cocaine use was significantly reduced with citicoline initially, although treatment effects diminished over time, suggesting the need for augmentation strategies to optimize long-term benefit.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998279     DOI: 10.1176/appi.ajp.2015.14070857

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

1.  Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders.

Authors:  Chengxi Li; Jayme M Palka; E Sherwood Brown
Journal:  J Affect Disord       Date:  2020-04-29       Impact factor: 4.839

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

3.  A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.

Authors:  Keming Gao; Stephen J Ganocy; Carla Conroy; Brittany Brownrigg; Mary Beth Serrano; Joseph R Calabrese
Journal:  Psychopharmacology (Berl)       Date:  2017-05-24       Impact factor: 4.530

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.

Authors:  E Sherwood Brown; Erin Van Enkevort; Alexandra Kulikova; Chastity Escalante; Alyson Nakamura; Elena I Ivleva; Traci Holmes
Journal:  Alcohol Clin Exp Res       Date:  2018-12-24       Impact factor: 3.455

6.  Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis.

Authors:  Brandon S Bentzley; Summer S Han; Sophie Neuner; Keith Humphreys; Kyle M Kampman; Casey H Halpern
Journal:  JAMA Netw Open       Date:  2021-05-03

Review 7.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

8.  Pharmacological Treatment of Mood Disorders and Comorbid Addictions: A Systematic Review and Meta-Analysis: Traitement Pharmacologique des Troubles de L'humeur et des Dépendances Comorbides: Une Revue Systématique et une Méta-Analyse.

Authors:  Paul R A Stokes; Tahir Jokinen; Sami Amawi; Mutahira Qureshi; Muhammad Ishrat Husain; Lakshmi N Yatham; John Strang; Allan H Young
Journal:  Can J Psychiatry       Date:  2020-04-17       Impact factor: 4.356

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.